Trevi Therapeutics Inc (TRVI) FinancialsTRVIFinancialTrevi Therapeutics Inc

Evaluating the bottom line, Trevi Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.66%, provide a clear picture of how effectively TRVI converts its operational activities into shareholder value.

In the context of the broader market, TRVI competes directly with industry leaders such as KOD and NUVB. With a market capitalization of $2.63B, it holds a leading position in the sector. When comparing efficiency, TRVI's gross margin of N/A stands against KOD's N/A and NUVB's 70.11%. Such benchmarking helps identify whether Trevi Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Trevi has shown impressive growth with a 1-year change of +130.95% and a year-to-date change of +41.21%. However, it is currently operating at a loss, with a forward P/E ratio of 0 and a negative EPS of -0.11 reported for Q2 2026.